These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10636795)

  • 1. Checkpoint gene linked to human cancer.
    Hagmann M
    Science; 1999 Dec; 286(5449):2433-4. PubMed ID: 10636795
    [No Abstract]   [Full Text] [Related]  

  • 2. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.
    Bell DW; Varley JM; Szydlo TE; Kang DH; Wahrer DC; Shannon KE; Lubratovich M; Verselis SJ; Isselbacher KJ; Fraumeni JF; Birch JM; Li FP; Garber JE; Haber DA
    Science; 1999 Dec; 286(5449):2528-31. PubMed ID: 10617473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome.
    Bougeard G; Limacher JM; Martin C; Charbonnier F; Killian A; Delattre O; Longy M; Jonveaux P; Fricker JP; Stoppa-Lyonnet D; Flaman JM; Frébourg T
    J Med Genet; 2001 Apr; 38(4):253-7. PubMed ID: 11370630
    [No Abstract]   [Full Text] [Related]  

  • 4. Li-Fraumeni syndrome: the genetics and treatment considerations for the sarcoma and associated neoplasms.
    Upton B; Chu Q; Li BD
    Surg Oncol Clin N Am; 2009 Jan; 18(1):145-56, ix. PubMed ID: 19056046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation.
    Goi K; Takagi M; Iwata S; Delia D; Asada M; Donghi R; Tsunematsu Y; Nakazawa S; Yamamoto H; Yokota J; Tamura K; Saeki Y; Utsunomiya J; Takahashi T; Ueda R; Ishioka C; Eguchi M; Kamata N; Mizutani S
    Cancer Res; 1997 May; 57(10):1895-902. PubMed ID: 9157982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
    Vahteristo P; Tamminen A; Karvinen P; Eerola H; Eklund C; Aaltonen LA; Blomqvist C; Aittomäki K; Nevanlinna H
    Cancer Res; 2001 Aug; 61(15):5718-22. PubMed ID: 11479205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell cycle. Piecing together the p53 puzzle.
    Carr AM
    Science; 2000 Mar; 287(5459):1765-6. PubMed ID: 10755928
    [No Abstract]   [Full Text] [Related]  

  • 8. Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome.
    Sodha N; Houlston RS; Bullock S; Yuille MA; Chu C; Turner G; Eeles RA
    Hum Mutat; 2002 Dec; 20(6):460-2. PubMed ID: 12442270
    [No Abstract]   [Full Text] [Related]  

  • 9. TP53, hChk2, and the Li-Fraumeni syndrome.
    Varley J
    Methods Mol Biol; 2003; 222():117-29. PubMed ID: 12710683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds.
    Siddiqui R; Onel K; Facio F; Nafa K; Diaz LR; Kauff N; Huang H; Robson M; Ellis N; Offit K
    Fam Cancer; 2005; 4(2):177-81. PubMed ID: 15951970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of tumor-associated Chk2 mutations.
    Wu X; Webster SR; Chen J
    J Biol Chem; 2001 Jan; 276(4):2971-4. PubMed ID: 11053450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.
    Lee SB; Kim SH; Bell DW; Wahrer DC; Schiripo TA; Jorczak MM; Sgroi DC; Garber JE; Li FP; Nichols KE; Varley JM; Godwin AK; Shannon KM; Harlow E; Haber DA
    Cancer Res; 2001 Nov; 61(22):8062-7. PubMed ID: 11719428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review).
    Nakanishi A; Kitagishi Y; Ogura Y; Matsuda S
    Int J Oncol; 2014 Jun; 44(6):1813-9. PubMed ID: 24718924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations.
    Delia D; Goi K; Mizutani S; Yamada T; Aiello A; Fontanella E; Lamorte G; Iwata S; Ishioka C; Krajewski S; Reed JC; Pierotti MA
    Oncogene; 1997 May; 14(18):2137-47. PubMed ID: 9174049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
    Frebourg T; Kassel J; Lam KT; Gryka MA; Barbier N; Andersen TI; Børresen AL; Friend SH
    Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6413-7. PubMed ID: 1631137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening hCHK2 for mutations.
    Sodha N; Williams R; Mangion J; Bullock SL; Yuille MR; Eeles RA
    Science; 2000 Jul; 289(5478):359. PubMed ID: 10939935
    [No Abstract]   [Full Text] [Related]  

  • 17. Reoxygenation following hypoxia activates DNA-damage checkpoint signaling pathways that suppress cell-cycle progression in cultured human lymphocytes.
    Kim BM; Choi JY; Kim YJ; Woo HD; Chung HW
    FEBS Lett; 2007 Jun; 581(16):3005-12. PubMed ID: 17544403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
    Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
    Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of genomic instability in preneoplastic cells.
    Tlsty TD
    Cancer Surv; 1996; 28():217-24. PubMed ID: 8977037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Li-Fraumeni syndrome: an inherited susceptibility to cancer.
    Evans SC; Lozano G
    Mol Med Today; 1997 Sep; 3(9):390-5. PubMed ID: 9302689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.